Online citations, reference lists, and bibliographies.
← Back to Search

Asbestos-Related Pleural Diseases: The Role Of Gene-Environment Interactions

V. Dolžan, A. Franko
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Several pleural diseases have been associated with asbestos exposure. Asbestos exposure may lead to the development of benign pleural diseases, such as pleural plaques, diffuse pleural thickening, and pleural effusion, as well as to the development of malignant mesothelioma, a highly aggressive tumour of the pleura. Asbestos exposure related to pleural diseases may be occupational or environmental. Although the causal relationship between asbestos-related pleural diseases and asbestos exposure has been well confirmed, the role of genetic factors in the development of these diseases needs to be further investigated and elucidated. The results of the studies performed so far indicate that in addition to asbestos exposure, genetic factors as well as the interactions between genetic factors and asbestos exposure may have an important impact on the risk of asbestos-related pleural diseases, especially malignant mesothelioma. This chapter aims to present how the risk of developing asbestos-related pleural diseases may be influenced by asbestos exposure, genetic factors, interactions between different genetic factors, as well as interactions between different genetic factors and asbestos exposure.
This paper references
10.1136/oem.42.9.612
Ventilatory decrements in former asbestos cement workers: a four year follow up.
C. Ohlson (1985)
10.1016/J.RMR.2011.06.015
Quels sont les objectifs du suivi post-professionnel, les bénéfices attendus et les risques possibles ? Objectifs médicaux en termes de morbidité, mortalité et qualité de vie
J.-C. Dalphin (2011)
10.1097/CAD.0b013e32834d7a1c
A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma
V. Kovač (2012)
10.7861/clinmedicine.14-1-68
Non-malignant asbestos-related diseases: a clinical view.
D. Fishwick (2014)
10.1093/JNCI/88.24.1853
Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
A. Hirvonen (1996)
10.1038/nrg1578
Gene–environment interactions in human diseases
D. Hunter (2005)
10.1093/ANNHYG/MEM003
A case control study of lung cancer and exposure to chrysotile and amphibole at a slovenian asbestos-cement plant.
M. Dodič Fikfak (2007)
10.21037/atm.2017.06.25
Malignant pleural mesothelioma: adjuvant therapy with radiation therapy.
K. Rosenzweig (2017)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1136/oem.52.1.20
Radiological changes in asbestos cement workers.
K. Jakobsson (1995)
10.1016/J.IJHEH.2006.03.002
Metabolic genotypes as modulators of asbestos-related pleural malignant mesothelioma risk: a comparison of Finnish and Italian populations.
M. Neri (2006)
10.1136/THX.52.6.507
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
10.1155/2017/6797826
Incidental and Underreported Pleural Plaques at Chest CT: Do Not Miss Them—Asbestos Exposure Still Exists
M. A. Mazzei (2017)
10.1016/J.ARBRES.2016.12.014
Recomendaciones sobre el diagnóstico y manejo de la enfermedad pleural y pulmonar por asbesto
C. D. Roza (2017)
10.1136/oem.45.3.182
Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death.
J. Ribak (1988)
10.1016/S0009-2797(00)00197-6
Epoxide hydrolases: biochemistry and molecular biology.
A. Fretland (2000)
10.1016/j.freeradbiomed.2015.05.002
Malignant mesothelioma as an oxidative stress-induced cancer: An update.
S. H. Chew (2015)
10.1093/IJE/DYM215
Investigating gene environment interaction in complex diseases: increasing power by selective sampling for environmental exposure.
M. Boks (2007)
10.1073/pnas.1006542107
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation
H. Yang (2010)
10.1016/B978-0-7216-8974-6.50050-6
Chapter 46 – Mineral Dusts: Asbestos, Silica, Coal, Manufactured Fibers
G. R. Wagner (2005)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1183/13993003.01254-2018
Investigating unilateral pleural effusions: the role of cytology
D. Arnold (2018)
10.1016/j.lungcan.2008.09.008
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
C. Lee (2009)
10.1183/09031936.96.09091932
The epidemiology of mesothelioma in historical context.
J. C. Mcdonald (1996)
10.2478/v10019-012-0032-0
Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients
V. Kovač (2012)
10.5772/66120
Gene-Environment Interactions: The Case of Asbestosis
V. Dolžan (2017)
10.2478/raon-2019-0009
Genetic Polymorphisms in Aquaporin 1 as Risk Factors for Malignant Mesothelioma and Biomarkers of Response to Cisplatin Treatment
Barbara Šenk (2019)
10.1016/S0272-5231(05)70079-4
Asbestos-induced pleural disease.
S. Nishimura (1998)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.1002/art.23286
Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases?
D. Verma (2008)
10.1093/AJE/KWI034
Predictors of lung cancer among asbestos-exposed men in the {beta}-carotene and retinol efficacy trial.
M. Cullen (2005)
Diagnosis and treatment of pleural mesothelioma. Seminars in Surgical Oncology
VW Rusch (1990)
10.1136/oemed-2016-104178
Pleural abnormalities in the Framingham Heart Study: prevalence and CT image features
T. Araki (2017)
10.1002/AJIM.4700220205
Localized pleural plaques and lung cancer.
T. Partanen (1992)
10.2478/raon-2018-0004
The Influence of Genetic Variability on the Risk of Developing Malignant Mesothelioma
A. Franko (2018)
10.3390/ijerph13050494
Prevention of Asbestos-Related Disease in Countries Currently Using Asbestos
D. Marsili (2016)
10.1023/A:1008845332422
Incidence of cancer among Finnish patients with asbestos-related pulmonary or pleural fibrosis
A. Karjalainen (2004)
10.1002/AJIM.4700230604
Diffuse thickening superimposed on circumscribed pleural thickening related to asbestos exposure.
A. Miller (1993)
10.3109/08958378.2015.1051640
Are pleural plaques an appropriate endpoint for risk analyses?
L. Maxim (2015)
10.1146/annurev.pharmtox.45.120403.095857
Glutathione transferases.
J. Hayes (2005)
10.1016/j.ajpath.2012.12.028
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.
B. Mossman (2013)
10.1259/bjr.20170218
The physiological consequences of different distributions of diffuse pleural thickening on CT imaging.
D. de Fonseka (2017)
Tumour necrosis factor-alpha gene polymorphisms in asbestosinduced diseases. Biomarkers
S Helmig (2010)
10.3109/1354750X.2010.481365
Tumour necrosis factor-α gene polymorphisms in asbestos-induced diseases
S. Helmig (2010)
10.21037/jtd.2017.10.09
Clinical diagnosis of malignant pleural mesothelioma.
A. Bianco (2018)
10.1155/2015/316739
Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma
K. Goričar (2015)
10.1378/CHEST.125.3.1103
Asbestos and the pleura: a review.
D. Cugell (2004)
10.1165/RCMB.2003-0409OC
Ultrastructural and chromosomal studies on manganese superoxide dismutase in malignant mesothelioma.
V. Kinnula (2004)
10.1146/annurev-publhealth-031811-124704
The worldwide pandemic of asbestos-related diseases.
L. Stayner (2013)
10.4081/jphr.2018.1519
Impact of asbestos on public health: a retrospective study on a series of subjects with occupational and non-occupational exposure to asbestos during the activity of Fibronit plant (Broni, Italy)
S. Visonà (2018)
10.1016/J.LUNGCAN.2004.04.007
Asbestos and mesothelioma in South Africa.
R. Abratt (2004)
10.1093/HMG/8.1.93
Genetic control of the circulating concentration of transforming growth factor type beta1.
D. Grainger (1999)
10.1056/NEJM198206173062409
Exposure to asbestos and human disease.
M. Becklake (1982)
10.1016/j.rmr.2011.04.008
Asbestos-related cancer risk in patients with asbestosis or pleural plaques.
J. Ameille (2011)
10.2478/raon-2019-0016
The Influence of Genetic Variability of DNA Repair Mechanisms on the Risk of Malignant Mesothelioma
Kristina Levpuscek (2019)
10.1136/oem.2005.020834
The effect of asbestosis on lung cancer risk beyond the dose related effect of asbestos alone
A. Reid (2005)
10.1586/17476348.2015.1081066
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies
A. Bononi (2015)
10.1590/S0100-879X2005001000009
Role of matrix metalloproteinases in the development of airway inflammation and remodeling.
V. Lagente (2005)
10.1016/j.rmcr.2018.12.006
Case report: Steroid responsive mesothelioma-related pleural effusion
M. Shehata (2019)
10.3233/DMA-2011-0866
Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
A. Franko (2012)
10.1183/09031936.00049810
Genetic susceptibility to asbestos-related fibrotic pleuropulmonary changes
M. Kukkonen (2010)
10.1148/RADIOLOGY.220.1.R01JL27237
Functional consequences of pleural disease evaluated with chest radiography and CT.
S. J. Copley (2001)
10.1378/CHEST.105.1.144
Pleural plaques and risk for bronchial carcinoma and mesothelioma. A prospective study.
G. Hillerdal (1994)
10.1164/AJRCCM.171.5.951
Diagnosis and initial management of nonmalignant diseases related to asbestos.
D. Weill (2005)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
Pathology of human malignant mesothelioma. Seminars in Oncology
Y. Suzuki (1981)
10.1136/thx.51.2.210
New developments in asbestos-related pleural disease.
R. Rudd (1996)
10.1080/10937404.2011.556051
Role of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases
Sarah X. L. Huang (2011)
10.1093/carcin/bgv097
Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
S. Tunesi (2015)
10.1002/SSU.2980060510
Diagnosis and treatment of pleural mesothelioma.
V. Rusch (1990)
10.1186/s12885-015-1519-z
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
G. Ak (2015)
10.1148/radiol.2462070712
Fleischner Society: glossary of terms for thoracic imaging.
D. Hansell (2008)
10.5271/sjweh.3471
Epidemics of asbestos-related diseases--something old, something new.
H. Vainio (2015)
10.2310/JIM.0b013e3181a4f32a
Association of Transforming Growth Factor β1 Gene Polymorphisms and Asbestos-Induced Fibrosis and Tumors
S. Helmig (2009)
10.1056/NEJM198206173062403
The pathogenesis of asbestos-associated diseases.
J. Craighead (1982)
10.1183/16000617.0063-2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
A. Bibby (2016)
10.3348/kjr.2015.16.5.1142
CT Characteristics of Pleural Plaques Related to Occupational or Environmental Asbestos Exposure from South Korean Asbestos Mines
Y. Kim (2015)
10.1093/jnci/djs513
Pleural plaques and the risk of pleural mesothelioma.
J. Pairon (2013)
10.1002/ijc.22590
Polymorphisms of glutathione‐S‐transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma
S. Landi (2007)
10.3389/fonc.2018.00091
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
Marika Rossini (2018)
10.1378/chest.46.1.78
ASBESTOS PLEURISY.
H. Eisenstadt (1964)
10.1136/jim-2017-000628
Biological responses to asbestos inhalation and pathogenesis of asbestos-related benign and malignant disease
Eduardo Solbes (2018)
10.1016/S0027-5107(02)00153-7
Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis.
D. Hein (2002)
10.3978/j.issn.2225-319X.2012.10.05
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.
A. Nowak (2012)
Mesothelioma mortality in Great Britain
DM McElvenny (1968)
10.1515/raon-2015-0019
Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma
V. Kovač (2015)
10.3200/AEOH.61.4.183-192
Pleural Plaques: A Review of Diagnostic Issues and Possible Nonasbestos Factors
C. C. Clarke (2006)
10.1146/annurev-pathol-020712-163942
Molecular basis of asbestos-induced lung disease.
G. Liu (2013)
10.1373/CLINCHEM.2006.079327
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
10.1155/2015/416179
Clinical Investigation of Benign Asbestos Pleural Effusion
N. Fujimoto (2015)
10.1289/EHP.97105S51313
Free radical activity of industrial fibers: role of iron in oxidative stress and activation of transcription factors.
P. Gilmour (1997)
10.1158/1940-6207.CAPR-15-0347
Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma
Yuwaraj Kadariya (2016)
10.1155/2017/8069529
Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma
Danijela Štrbac (2017)
10.1002/FOOD.19760200618
Iarc Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. Vol. 8: Some Aromatic Azo Compounds. 357 Seiten. International Agency for Research on Cancer, Lyon 1975. Preis: 36,- Sw.fr
W. Fritz (1976)
10.1016/S0304-3835(01)00819-9
Manganese superoxide dismutase genotypes and asbestos-associated pulmonary disorders.
A. Hirvonen (2002)
10.1136/oemed-2013-101555
Genes involved in innate immunity associated with asbestos-related fibrotic changes
M. Kukkonen (2013)
10.1016/J.ARBR.2017.05.017
Recommendations for the Diagnosis and Management of Asbestos-Related Pleural and Pulmonary Disease.
Carmen Diego Roza (2017)
10.1159/000364948
Asbestos-Related Diffuse Pleural Thickening
N. Fujimoto (2014)
10.5555/URI:PII:0093775481900361
Pathology of human malignant mesothelioma.
Y. Suzuki (1981)
10.1136/oem.49.2.144
An update of cancer mortality among chrysotile asbestos miners in Balangero, northern Italy.
R. Calisti (1992)
10.1016/j.mrfmmm.2011.01.001
XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study.
M. Betti (2011)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma.
A. Hirvonen (1995)
10.1136/oemed-2011-100316
Associations between radiographic findings and spirometry in a community exposed to Libby amphibole
Theodore C. Larson (2012)
5772 / intechopen . 88193 polymorphisms as baseline risk predictors in malignant pleural mesothelioma
D Strbac
10.1136/oem.50.8.673
Mechanisms of asbestos carcinogenesis and toxicity: the amphibole hypothesis revisited.
B. Mossman (1993)
10.1289/EHP.97105S51003
Mineral properties and their contributions to particle toxicity.
G. Guthrie (1997)
10.1186/s12989-016-0162-4
The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases
M. Sayan (2016)
10.1016/j.amjms.2017.03.033
The Effects of Pleural Plaques on Longitudinal Lung Function in Vermiculite Miners of Libby, Montana
K. A. Clark (2017)
10.1016/J.MRFMMM.2006.02.005
Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study.
I. Dianzani (2006)
10.1093/OCCMED/KQI034
Mesothelioma mortality in Great Britain from 1968 to 2001.
D. McElvenny (2005)
10.1046/j.1365-2796.2001.00839.x
The role of gene–environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast
L. Mucci (2001)
Latency periods in asbestos-related mesothelioma of the pleura.
C. Bianchi (1997)
10.1136/oem.29.2.142
A mortality study of shipyard workers with pleural plaques
D. Fletcher (1972)
10.5271/SJWEH.186
Asbestos, asbestosis, pleural plaques and lung cancer.
G. Hillerdal (1997)
10.1073/PNAS.94.7.3195
Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.
A. Wilson (1997)
10.1097/MCP.0b013e32834e897d
Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases
V. Antao (2012)
10.2214/AJR.144.1.9
Diffuse pleural thickening in an asbestos-exposed population: prevalence and causes.
T. Mcloud (1985)
10.2478/raon-2018-0005
Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma
Danijela Štrbac (2018)
10.1016/j.lungcan.2018.03.009
Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
Sophie Sneddon (2018)
10.1016/J.AOGH.2016.01.019
The global health dimensions of asbestos and asbestos-related diseases.
K. Takahashi (2016)



Semantic Scholar Logo Some data provided by SemanticScholar